To evaluate the diagnostic significance of tumor marker CA-125 in patients with pelvic masses, we measured preoperative serum CA-125 level in patients who underwent operations due to pelvic masses from July 1987 to June 1995. Serum CA-125 level
of
35u/ml was determined as cut-off levels.
@ES The following results were obtained.
@EN 1. The histology of pelvic masses in 253 study patients consisted of 216 benign(85%) and malignant masses 37(15%).
2. CA-125 levels of the benign pelvic masses and malignant pelvic masses were 63.8u/ml and 231.2u/ml respectively. These differences were statistically significant. (p<0.05)
3. Using 35u/ml as a cutoff, the false positivity of malignant ovarian tumor was 81.1%.
4. In contrast to the mean (CA-125) concentration of mucinous adenocarcinoma of 154.8u/ml, the mean CA-125 concentration of non-mucinous adenocarcinoma was 266.5u/ml There was a statistically significant difference between these two groups.
5. Using 35u/ml as a cutoff, the positivity according to FIGO staging was 9 out of 15cases (60%) in stage I, 4 out of 4 cases(100%) in stage II, 14 out of 16cases (87.5%) in stage III, and 2 out of 2 cases (100%) at stage IV.
6. When the cut off point of CA-125 concentration was decided as 35u/ml, sensitivity, specificity, positive predictive value, and diagnostic efficiency of CA-125 concentration for malignant ovarian tumor were 81.08%, 58.33%, 27.27%, 94.12%, and
56.13%
respectively.
Our results suggest that CA-125 assay can be used only as a diagnostic adjunct for discriminating benign from malignant ovarian tumors.
|